Physician profile
Adolph Meyer
NPI 1639194996
$8,332.47
in general payments reported to CMS, 2019-2025
37 companies · $1,753 in 2025
The $1,753 reported for 2025 was more than what 92% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,388 · 2020: $262 · 2021: $392 · 2022: $836 · 2023: $1,981 · 2024: $1,720 · 2025: $1,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,454.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $799.85 | 2019-2025 | |
| Amgen INC. | $778.29 | 2021-2025 | Krystexxa, Uplizna |
| E.R. Squibb & Sons, L.L.C. | $510.16 | 2024-2025 | Zeposia, Cobenfy |
| Glaxosmithkline, LLC. | $481.75 | 2019-2023 | Arexvy, Shingrix |
| Paratek Pharmaceuticals, INC. | $374.50 | 2022-2024 | Nuzyra |
| Horizon Therapeutics Plc | $373.82 | 2019-2023 | Krystexxa, Uplizna |
| Emd Serono, INC. | $370.50 | 2023-2024 | Mavenclad, Mavenclad |
| Abbvie INC. | $364.87 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $259.38 | 2022-2023 | Ongentys |
| Tg Therapeutics, INC. | $255.36 | 2024-2025 | |
| Abbott Laboratories | $251.97 | 2022-2023 | Diamondback Peripheral |
| Lundbeck LLC | $249.81 | 2025 | Vyepti |
| Vanda Pharmaceuticals INC. | $249.31 | 2024-2025 | Ponvory |
| Novartis Pharmaceuticals Corporation | $222.04 | 2019 | |
| Biogen, INC. | $196.64 | 2023-2024 | Vumerity |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $180.79 | 2023-2024 | Austedo Xr, Uzedy |
| Stryker Corporation | $166.67 | 2023 | Mako |
| Aroa Biosurgery Incorporated | $153.21 | 2020 | |
| Ge Healthcare | $138.92 | 2022 | |
| Treace Medical Concepts, INC. | $135.46 | 2022 | |
| Genzyme Corporation | $132.55 | 2019 | |
| Genentech USA, INC. | $129.38 | 2019 | |
| Polynovo North America LLC | $127.13 | 2024 | Novosorb Btm |
| Organogenesis INC. | $125.00 | 2021 | |
| Evofem Biosciences, INC. | $125.00 | 2021 | |
| Kyowa Kirin, INC. | $124.99 | 2023 | Nourianz |
| Vertex Pharmaceuticals Incorporated | $121.91 | 2025 | |
| Ani Pharmaceuticals, INC. | $120.68 | 2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $117.84 | 2025 | Symbravo |
| Corium, LLC | $116.62 | 2023 | Adlarity |
| Biotissue Holdings INC. | $110.58 | 2022 | |
| Celgene Corporation | $110.39 | 2019 | |
| Tactile Systems Technology INC | $108.61 | 2020 | |
| Wright Medical Technology, INC. | $97.89 | 2019 | |
| Medtronic Vascular, INC. | $86.31 | 2019 | |
| Polarityte, INC. | $46.93 | 2019 | |
| Kerecis Limited | $17.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adolph Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.